What Happened?
Cambridge, MA-based Gemini-Therapeutics Appointed James McLaughlin as President and Chief Executive Officer
About the Company
Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics.
About the Person
James McLaughlin is President and Chief Executive Officer at Gemini Therapeutics. Previously, James held various senior HR leadership roles in the industry.
Info Source
News
Short Profile